What Is Essential Thrombocythemia (ET)? Symptoms, Causes, and Treatments

A Blood Disorder That Is Often Silent but Can Be Dangerous

Essential thrombocythemia (ET) is a rare blood disorder that often progresses without symptoms but can cause serious complications. It is characterized by uncontrolled production of platelets, the small blood cells involved in clotting. It is a subtype of a group of bone marrow cancers called “myeloproliferative neoplasms (MPNs).” These cancers originate in the bone marrow.

Although it may cause no symptoms initially, over time it can lead to blood clots, bleeding, and even stroke or other life-threatening conditions. Early diagnosis and appropriate treatment can therefore have a positive effect on the course of ET.

A Brief Clarification

Essential thrombocythemia and essential thrombocytosis are often used interchangeably, although there is a subtle distinction between them.

• Essential thrombocythemia (ET): A clinically and hematologically defined myeloproliferative neoplasm (MPN), which belongs to this group of disorders and is cancer-like in nature.
• Thrombocytosis: An increased platelet count. It is a sign or laboratory finding,rather than the name of a disease.

What Is Essential Thrombocythemia?

ET develops when the bone marrow greatly increases platelet production. Normally, platelets form clots to stop bleeding when blood vessels are damaged. In ET, however, their numbers rise so much that the clotting system becomes unbalancedand can cause both clot formation(thrombosis) and excessive bleedingas a result.

A Genetically Based Disorder

Genetic mutations underlie this uncontrolled production. The most common mutations are:

• JAK2 mutation (55%): Causes proteins involved in blood cell production to become overactive.
• CALR mutation: More common in younger people and generally associated with a lower risk of complications.
• MPL mutation: A rare mutation affecting the receptor that regulates platelet production.

In approximately 10% of patients, none of these three mutations is present. This is called “triple-negative ET,” and its cause has not yet been fully explained.

Who Is at Risk?

ET can occur at any age, but is most often diagnosed between ages 50-60. The average age at diagnosis is 65. It occurs 1.5 times as often in women as in men.

Essential thrombocythemia (ET) is a rare myeloproliferative neoplasm, with an annual worldwide incidence ranging from 1 to 2.5 per 100,000 people. Specific data on ET incidence in Turkey are difficult to obtain. However, publications from the Turkish Society of Hematology also give a general ET incidence of 1-2.5 per 100,000 people. It may therefore be reasonable to think that the incidence in Turkey is similar.

Symptoms: Often Silent at First, but Potentially Dangerous

Most patients learn they have the disease incidentally through routine blood tests. Symptoms generally appear when complications related to clotting or bleeding develop. Common symptoms include:

Symptoms caused by clots:

• Headache
• Dizziness
• Weakness or numbness on one side of the body
• Vision problems (blurred or double vision)
• Speech problems
• Pain, swelling, and discoloration in an arm or leg

Symptoms caused by bleeding:

• Nosebleeds and bleeding gums
• Easy bruising
• Blood in the stool or urine
• Heavy menstrual bleeding
• Burning or tingling in the hands and feet (erythromelalgia)
• Purplish skin lesions

Other symptoms:

• Chest pain
• Shortness of breath
• Fatigue
• Weight loss
• Night sweats
• Enlarged spleen
• Fever and nausea

When Should You See a Doctor?

If any of these symptoms occur, particularly if a blood clot or bleeding is suspected, consult a hematologist without delay. This is because early diagnosisis critically important in preventing serious complications.

Causes of ET: Genetic Mutations Play a Central Role

ET is generally not inherited, but develops as a result of genetic mutations that arise in adulthood. These mutations cause bone marrow cells to produce more platelets than normal.

Environmental factors, such as prolonged exposure to toxins or radiation, are thought to potentially trigger these mutations, but more research is needed.

Treatment: An Individualized Approach Based on Risk

The main aims of ET treatment are to prevent complications such as blood clots and bleeding, minimize side effects and improve the patient's quality of life. The treatment plan depends on factors such as the patient's:

• Age
• History of clots or bleeding
• Current symptoms
• Genetic test results
• Other chronic conditions

and related clinical circumstances.

Low-Risk Patients (Under 60, No History of Clots)

• Observation without medication: Regular follow-up alone may be sufficient.
• Aspirin (low dose): May be recommended in mild cases to prevent clots.
• Lifestyle changes: Quitting smoking and controlling high blood pressure, diabetes, and cholesterol are important.

High-Risk Patients

• Hydroxyurea: A drug with a chemotherapeutic effect and the most commonly used first-line treatment.
• Anagrelide: An alternative in capsule form, specifically aimed at lowering platelets alone. However, it may cause side effects such as headaches and heart rhythm disturbances.
• Busulfan: Used for patients who cannot tolerate hydroxyurea. However, long-term use may carry a risk of leukemia as a potential complication.
• Peginterferon alfa 2a: Regulates platelet production by stimulating the immune system and is preferred particularly in younger patients.

Possible Complications

Without treatment, ET can cause the following serious conditions:

• Clots within blood vessels (thrombosis): Stroke, heart attack, or deep vein thrombosis
• Bleeding: An excessively high platelet count can disrupt clotting.
• Disease progression: In some patients, ET can develop into more serious blood disorders, such as myelofibrosis or acute myeloid leukemia, as the disease progresses.
• Pregnancy complications: Increased risks of miscarriage, preeclampsia, or impaired fetal growth.

Disease Course and Quality of Life

Although ET cannot yet be completely cured, it is a condition that can be effectively controlled. With appropriate treatment and regular follow-up, most patients can have a normal or near-normal life expectancy despite the condition.

Can It Be Prevented?

There is currently no way to prevent ET completely. However, steps can be taken to reduce the risk of complications, including:

• Healthy eating
• Regular exercise
• Quitting smoking and alcohol
• Keeping chronic conditions under control
• Regular blood tests for people with a family history of ET or MPNs

Conclusion: Early Diagnosis Saves Lives

Essential thrombocythemia is a blood disorder that often progresses without symptoms, but can have serious consequences if left untreated. Early diagnosisis the key to preventing complications.

If you or someone close to you has symptoms resembling those of ET, consult a hematologist. With proper management, a long and healthy life with ET is possible.